Pulmonary Epithelioid Haemangioendothelioma and Bevacizumab  by Belmont, Laure et al.
been described in EGFR-TKIs treated pa-
tients, especially with Staphylococcus au-
reus nasal carriage or extensive midface
involvement.5 Inhibition of EGFR signal-
ing on epidermal and adnexal epithelium
may lead to skin barrier impairment with
increased bacterial carriage. Then, it is still
unclear if EGFR-TKIs-induced skin le-
sions increase P. acnes colonization or if
P. acnes is directly involved in skin tox-
icity as it is in acnea vulgaris. Topical and
systemic antibiotics have been used to
treat these skin lesions.2 Interestingly, tet-
racycline is used mostly for its immuno-
modulatory properties, but its antibiotic
activity against P. acnes could prevent the
risk of invasive infections. Moreover, pro-
phylactic treatment should be considered
before piercing an altered skin to decrease
bacterial carriage and therefore, the risk of
bacterial seeding.
We describe the first case of P.
acnes pleural empyema associated with
EGFR-TKIs. Increasing use of these
molecules should warn clinicians of this
rare but potentially lethal complication
especially with thoracocenteses.
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Pulmonary Epithelioid
Haemangioendothelioma
and Bevacizumab
To the Editor:
Pulmonary epithelioid hemangioen-
dothelioma (PEH) is a rare tumor of the
lung.1 Surgery is proposed in case of
unilateral nodules.2 In case of bilateral
nodules and/or pleural involvement,
several antineoplastic agents have been
used with poor beneficial effects in most
cases.3 Because PEH is a vascular tu-
mor, the use of antiangiogenic therapy
may be suggested. So, we report here the
first case, to our knowledge, of a patient
treated with bevacizumab and chemo-
therapy.
A 41-year-old man was admitted
for fever, cough, and breathlessness.
His weight had fallen by 4 kg. Chest
radiograph and thoracic computed to-
mography scan showed numerous bi-
lateral calcified nodules, condensation
in the right lower lobe, alveolar infil-
trate predominant in the left upper
lobe, and bilateral pleural effusion
(Figure 1). Positron-emission tomog-
raphy exhibited an increased uptake of
18F-fluorodeoxyglucose in the con-
densation of the right lower lobe and
pleura. Bronchoscopy with bronchoal-
veolar lavage and bronchial biopsies
were normal. Thoracocentesis revealed
bloody fluid without malignant cells.
A right thoracoscopy was performed.
Histologic examination of the pleural
and pulmonary biopsies showed simi-
lar features with monomorphic malig-
nant proliferation made up of cells
with nuclear pleomorphism and rare
atypical mitoses surrounding the ves-
sels. Staining of the tumoral tissues
was positive for antivimentin and anti-
CD34 antibodies, and negative for an-
ticytokeratin antibodies. These findings
supported the diagnosis of epithelioid
hemangioendothelioma. Expression of
vascular epithelium growth factor recep-
tor was highly positive.
The patient started chemother-
apy with cisplatin and etoposide for
one cycle. Because of progressive dis-
ease, he received interferon alpha for 1
month. However, his disease progressed
and he was started with bevacizumab
(450 mg). Thereafter, he remained sta-
ble and a combination of carboplatin-
paclitaxel with bevacizumab (15 mg/kg)
was given on day 1.
Chemotherapy was repeated every
21 days for five cycles. The patient
showed a dramatic improvement in clin-
ical status. The thoracic computed to-
mography scan revealed a good partial
response (Figure 2).
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FIGURE 1. Thoracic computed tomography scan performed before bevaci-
zumab showing bilateral pleural effusion, condensation with a small cavity in
the right-lower lobe, peripheral opacity in the middle lobe with round glass
opacities.
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Since the patient complained of
paresthesia related to chemotherapy, be-
vacizumab was given alone for four cy-
cles. A neurologic improvement made it
possible to give bevacizumab with car-
boplatin-docetaxel for more three cy-
cles. Up to now, he has remained stable,
13 months after the initial diagnosis.
Various chemotherapies have pre-
viously been reported for unresectable
or metastatic PEH: doxorubicin, vinorel-
bine, carboplatin-etoposide, doxorubi-
cin-ifosfamide-dacarbazine, followed by
intensification, paclitaxel-gemcitabine.
These treatments showed variable ef-
fectiveness,3 and therefore no standard
therapeutic guidelines are available.
Because of the vascular component of
PEH, thalidomide and interferon alpha
have also been proposed for unresect-
able cases. According to the hypothe-
sis of a major role for the vascular
component in the dissemination of
PEH, we suggest that new antiangio-
genic therapies should be considered
for patients with advanced PEH.4
Moreover, we highlight that no ad-
verse events occurred after 13 cycles
of bevacizumab.
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FIGURE 2. Thoracic computed tomography scan performed after five cycles of
cisplatin, etoposide, and bevacizumab, showing improvement of the bilateral pleu-
ral effusion, a decrease of the middle lobe opacity and the right lower lobe opacity
with an increase of the cavity (arrow).
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